Genmab
kr 2,257.00Change from previous close: −2.42%Absolute change: −kr 56.00
At a glance
- Revenue growth
- +19.19%
- 2025 vs 2024
- Net income growth
- −15.00%
- 2025 vs 2024
- Net margin
- 25.9%
- 2024: 36.3%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | 3,720 | 3,121 | 2,390 | 2,084 | 1,287 |
| Cost of revenue | 238 | 143 | 33.0 | 0.0 | — |
| Gross profit | 3,482 | 2,978 | 2,357 | 2,084 | 1,287 |
| Selling, general and administrative | 626 | 549 | 478 | 384 | 196 |
| Research and development | 1,606 | 1,414 | 1,107 | 799 | 640 |
| Operating income | 1,250 | 1,015 | 772 | 900 | 452 |
| EBIT | 1,250 | 1,015 | 772 | 900 | 452 |
| EBITDA | 1,290 | 1,052 | 802 | 942 | 481 |
| Interest expense | 61.0 | 18.0 | 10.0 | 5.6 | 2.0 |
| Pre-tax income | 1,204 | 1,326 | 817 | 998 | 599 |
| Income tax | 241 | 193 | 186 | 215 | 147 |
| Net income | 963 | 1,133 | 631 | 783 | 452 |
| Net income to common shareholders | 963 | 1,133 | 631 | 783 | 452 |
| Basic EPS | 15.49 | 17.65 | 9.66 | 11.98 | 6.92 |
| Diluted EPS | 15.37 | 17.53 | 9.58 | 11.87 | 6.85 |
| Average shares (basic) | 62.2 | 64.2 | 65.3 | 65.4 | 65.4 |
| Average shares (diluted) | 62.7 | 64.7 | 65.9 | 66.0 | 66.0 |